ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
7,948.20
-1.81%
S&P ASX All Technology
3,629.80
-3.15%
Brent Oil
70.235
0.00%
US Dollar vs AUD
1.59084
0.00%
Bitcoin
85,861.57
-0.34%
Pepperstone
Advertisement
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Viridian Therapeutics Inc (VRDN) Share Price

Viridian Therapeutics Inc

Viridian Therapeutics Inc (VRDN)

Viridian Metals Inc
Viridian Metals Inc
15.94
0.06
(0.38%)
Closed 09 March 8:00AM
Delayed by 15 minutes
15.90
-0.04
(-0.25%)
After Hours: 9:59AM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
15.90
Bid
15.10
Offer
24.45
Volume
1,008,806
15.52 Day's Range 16.50
11.40 52 Week Range 27.20
Market Cap
1.259B
Previous Close
15.88
Open
15.80
Last Trade
1
@
15.91
Last Trade Time
Financial Volume
US$ 16,209,932
VWAP
16.0684
Average Volume (3m)
1,344,051
Shares Outstanding
79,212,747
Dividend Yield
-
PE Ratio
-5.30
Earnings Per Share (EPS)
-3
Revenue
314k
Net Profit
-237.73M

About Viridian Therapeutics Inc

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being de... Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease. Show more

Sector
Medical Laboratories
Industry
Medical Laboratories
Website
www.viridiantherapeutics.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Viridian Therapeutics Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker VRDN. The last closing price for Viridian Therapeutics was US$15.88. Over the last year, Viridian Therapeutics shares have traded in a share price range of US$ 11.40 to US$ 27.20.

Viridian Therapeutics currently has 79,212,747 shares in issue. The market capitalisation of Viridian Therapeutics is US$1.26 billion. Viridian Therapeutics has a price to earnings ratio (PE ratio) of -5.30.

Ask ADVFN Intelligence (AI)

VRDN Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
05 March 2025
VRDN (0.38%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
05 March 2025
VRDN (0.38%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
05 March 2025
VRDN (0.38%)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Edgar (US Regulatory)
04 March 2025
VRDN (0.38%)

Form S-8 - Securities to be offered to employees in employee benefit plans
Edgar (US Regulatory)
04 March 2025
VRDN (0.38%)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Edgar (US Regulatory)
03 March 2025
VRDN (0.38%)

Form 8-K - Current report
Edgar (US Regulatory)
27 February 2025
VRDN (0.38%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.674.3992120814215.2316.1514.05105672015.21435634CS
4-2.59-14.007571660418.4918.5714.0593061016.16212279CS
12-1.92-10.774410774417.8223.6514.05134405118.65107324CS
261.8112.845990063914.0927.213.77140989620.12874664CS
52-2.86-15.245202558618.7627.211.4118501717.86614468CS
156-0.95-5.6379821958516.85399.4782247419.69460577CS
260-5.49-25.666199158521.39399.4762377619.53703645CS

VRDN - Frequently Asked Questions (FAQ)

What is the current Viridian Therapeutics share price?
The current share price of Viridian Therapeutics is US$ 15.90
How many Viridian Therapeutics shares are in issue?
Viridian Therapeutics has 79,212,747 shares in issue
What is the market cap of Viridian Therapeutics?
The market capitalisation of Viridian Therapeutics is USD 1.26B
What is the 1 year trading range for Viridian Therapeutics share price?
Viridian Therapeutics has traded in the range of US$ 11.40 to US$ 27.20 during the past year
What is the PE ratio of Viridian Therapeutics?
The price to earnings ratio of Viridian Therapeutics is -5.3
What is the cash to sales ratio of Viridian Therapeutics?
The cash to sales ratio of Viridian Therapeutics is 3.98k
What is the reporting currency for Viridian Therapeutics?
Viridian Therapeutics reports financial results in USD
What is the latest annual turnover for Viridian Therapeutics?
The latest annual turnover of Viridian Therapeutics is USD 314k
What is the latest annual profit for Viridian Therapeutics?
The latest annual profit of Viridian Therapeutics is USD -237.73M
What is the registered address of Viridian Therapeutics?
The registered address for Viridian Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Viridian Therapeutics website address?
The website address for Viridian Therapeutics is www.viridiantherapeutics.com
Which industry sector does Viridian Therapeutics operate in?
Viridian Therapeutics operates in the MEDICAL LABORATORIES sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ABLVAble View Global Inc
US$ 1.73
(137.18%)
5.14M
SUNESUNation Energy Inc
US$ 0.402999
(127.55%)
482.05M
BTOGBit Origin Ltd
US$ 0.6117
(118.46%)
622.67M
DWTXDogwood Therapeutics Inc
US$ 6.63
(49.66%)
25.92M
KZIAKazia Therapeutics Ltd
US$ 1.1899
(40.80%)
4.5M
ALBTAvalon GloboCare Corporation
US$ 6.96
(-36.15%)
577.55k
SCNXScienture Holdings Inc
US$ 1.55
(-35.68%)
1.59M
ACXPAcurx Pharmaceuticals Inc
US$ 0.4572
(-29.88%)
1.18M
RETOReTo Eco Solutions Inc
US$ 5.42
(-27.73%)
108.27k
OCTOEightco Holdings Inc
US$ 1.08
(-27.03%)
336.99k
BTOGBit Origin Ltd
US$ 0.6117
(118.46%)
622.67M
SUNESUNation Energy Inc
US$ 0.402999
(127.55%)
482.05M
NVDANVIDIA Corporation
US$ 112.69
(1.92%)
341.94M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 10.675
(-0.70%)
143.04M
ICONIcon Energy Corporation
US$ 0.169898
(17.17%)
142.23M

VRDN Discussion

View Posts
Monksdream Monksdream 6 months ago
VRDN more upside possible

👍️0
it_happens it_happens 6 months ago
Touched 20s today. Maybe it will stay above 20 tomorrow
👍️0
power11 power11 6 months ago
LOW 20'S BY WEEKEND IMO !!!
GOOD LUCK
👍️0
it_happens it_happens 6 months ago
Good news. I don't think that this is merely a one-day runner.
👍️0
power11 power11 6 months ago
BTIG RESEARCH ADJUST PRICE TARGET TO 56 FROM 46; STRONG BUY !!
👍️0
it_happens it_happens 6 months ago
Over 15 and having a good day today
👍️0
Monksdream Monksdream 6 months ago
VRDN under $15
👍️0
Apprentice Apprentice 3 years ago
I put into it a lot of $
423 shares!
👍️0
Apprentice Apprentice 3 years ago
It just doesn't want to move above $18
Yet, it's not diving much either.
What do you think at this point? Sell temporarily and by later low?
My average is too high @17.76 !
👍️0
crudeoil24 crudeoil24 3 years ago
Viridian Therapeutics, Inc., formerly Miragen Therapeutics, Inc., is a biotechnology company. The Company is engaged in developing multiple product candidates to treat patients who suffer from thyroid eye disease (TED), a debilitating orphan disease, and has early-stage programs focused on other targets and indications. Its lead candidate, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody (mAb) that is under development for thyroid eye disease (TED). The Company's TED pipeline also includes VRDN-002 and VRDN-003. Its other programs include VRDN-004, which is under development for undisclosed rare orphan disease, and VRDN-005, which is under development for tick-borne disease (TBD). The Company also out licenses its programs.
👍️0

Your Recent History

NASDAQ
VRDN
Viridian Therapeutics
COIN
POLIUSD
Polinate
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads